Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019045575) IMPROVEMENTS IN IGF-1 ANALYSIS, ADJUSTMENT AND DISEASE MANAGEMENT OF NON-NEUROLOGICAL AND/OR NEUROLOGICAL CONDITIONS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/045575 International Application No.: PCT/NZ2018/050116
Publication Date: 07.03.2019 International Filing Date: 28.08.2018
IPC:
A61K 38/12 (2006.01) ,A61K 36/18 (2006.01) ,A61P 25/28 (2006.01) ,A61P 9/12 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
04
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
12
Cyclic peptides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
36
Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
18
Magnoliophyta (angiosperms)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
28
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9
Drugs for disorders of the cardiovascular system
12
Antihypertensives
Applicants:
VITALITY WELLNESS (NZ) LIMITED [NZ/NZ]; Prosser Quirke 6 Blake Street 7400 Rangiora, NZ
Inventors:
GUAN, Jian; NZ
Agent:
CREATEIP; PO Box 21445 Edgeware 8143 Christchurch, NZ
Priority Data:
73500228.08.2017NZ
74231107.05.2018NZ
Title (EN) IMPROVEMENTS IN IGF-1 ANALYSIS, ADJUSTMENT AND DISEASE MANAGEMENT OF NON-NEUROLOGICAL AND/OR NEUROLOGICAL CONDITIONS
(FR) AMÉLIORATIONS DE L'ANALYSE D'IGF-1, DE L'AJUSTEMENT ET DE LA GESTION DE MALADIE D'ÉTATS NON NEUROLOGIQUES ET/OU NEUROLOGIQUES
Abstract:
(EN) Described herein are improvements relating to IGF-1 analysis, adjustment and disease management of non-neurological and/or neurological conditions. More specifically, methods relating to the clinical application of cyclic glycine-proline (cGP) biomarker for prediction of risk and recovery of non- neurological and/or neurological conditions with IGF-1 dysfunction and the use of a cGP containing organic or plant based material such as concentrated extract of blackcurrant anthocyanins (BCA) for the treatment of same. The methods more accurately measure IGF-1 function in vivo indirectly using cGP and cGP/IGF-1 ratio along with a means to adjust cGP and cGP/IGF-1 ratio (and hence active IGF-1 concentration), and specific treatment methods for individuals with a lower or reduction of cGP level relative to a standard set of baseline data.
(FR) La présente invention concerne des améliorations se rapportant à l'analyse d'IGF1, à l'ajustement et à la gestion de maladie d'états non neurologiques et/ou neurologiques. Plus spécifiquement, l'invention concerne des procédés se rapportant à l'application clinique du biomarqueur glycine-proline cyclique (cGP) pour la prédiction du risque et de la récupération d'états non neurologiques et/ou neurologiques avec un dysfonctionnement de l'IGF -1 et l'utilisation d'un matériau à base organique ou végétale contenant cGP tel qu'un extrait concentré d'anthocyanines de cassis (BCA) pour le traitement de ceux-ci. Les procédés mesurent plus précisément la fonction d'IGF -1 in vivo indirectement à l'aide de cGP et du rapport et cGP/IGF-1, conjointement avec un moyen pour ajuster le rapport cGP et cGP/IGF-1 (et donc la concentration active d'IGF-1), et des méthodes de traitement spécifiques pour des individus présentant un taux de cGP inférieur ou une réduction de celui-ci par rapport à un ensemble standard de données de ligne de base.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)